Edwards Lifesciences: Volume Spike Drives Pullback.
Edwards Lifesciences (EW) experienced elevated trading volume and several days of share-price decline in early February 2026, underperforming peers despite solid fundamentals and recent product approvals. Key drivers include heightened investor rebalancing, the commercial ramp of SAPIEN M3, and upcoming clinical data and guidance milestones.
